NONTHORACOTOMY DEFIBRILLATOR IMPLANTATION - A SINGLE-CENTER EXPERIENCE WITH 200 PATIENTS

Nonthoracotomy leads for defibrillator implantation and biphasic shocking devices are under investigation. Implantation success and mortality and morbidity of the procedure determine the operative course. Lead-associated complications, late infection, and freedom of sudden cardiac death characterize the follow-up period with respect to the implanted device. From October 1989 to March 1993 in 200 patients, 205 (including five infections caused by reimplantations) transvenous or transvenous-subcutaneous lead systems were tested. Mean ejection fraction was 0.40 +/- 0.16. In 62.5% (125/200) coronary artery disease and in 19% (38/200) cardiomyopathy was the underlying disease (59 patients with prior cardiac operations). Leads were implanted with defibrillation thresholds less than 25 J in 195 patients, whereas 10 patients received intrathoracal patches. Since biphasic shocks became available, no nonthoracotomy lead system has failed in the last 115 consecutive patients. Perioperative mortality in the nonthoracotomy group was 1% (2/195). In 6.2% (12/193) of the surviving patients, perioperative complications occurred. Major problems were bleeding from the device or patch pocket (n = 6) and early infection (n = 2). During the follow-up of 20 +/- 10 months, lead-associated complications (dislocation, lead fracture, insulation defect, loss of sensing) occurred in 9 patients and in 5 patients late infection appeared. Within the follow-up period no patient died suddenly, and 134 patients received therapeutic interventions by the device. Defibrillator implantation using nonthoracotomy leads, especially combined with biphasic shocking devices, is applicable in almost every patient. During the operative course and follow-up, the defibrillator-associated morbidity and mortality is at the same level as or lower than when using patch lead systems.